The Evolution of STI Testing: A Catalyst for Modern Diagnostic Technologies
NAAT-based confirmation can identify infection 6–19 days earlier than antigen- or antibody-based tests, marking a significant advancement toward faster, more reliable HIV diagnosis. Together, these evolving algorithms demonstrate how improvements in sensitivity, automation and workflow integration continue to narrow the diagnostic window. These advancements are now informing innovation across the broader field of infectious disease testing.
are now approved as confirmatory tests, including the Aptima HIV-1 Quant Dx (Hologic), cobas HIV-1/HIV-2 Qualitative (Roche) and Alinity m HIV-1 (Abbott) systems. These assays achieve near 100% specificity with detection limits of approximately 12–20 copies/mL, 11, 12 outperforming older quantitative viral load assays and offering the ability to differentiate between HIV-1 and HIV-2 where relevant.
Catalog
High-Performance Reagent Solutions for Molecular and Serological STI Testing
STI detection requires assays that can perform reliably across diverse targets and clinical presentations. While certain pathogens are best identified through molecular amplification, others demonstrate stronger detection profiles with serology-based methods. Meridian provides validated solutions for both, offering a comprehensive portfolio of high-performance reagents to support sensitive, specific and scalable STI testing. Explore our end-to-end reagent capabilities, including:
• Reagents designed for high sensitivity, low background and strong analytical specificity • Solutions supporting both centralized laboratories and decentralized testing workflows
• Molecular master mixes and enzymes optimized for pathogen detection • High-quality antigens and antibodies for robust immunoassay performance
Discover how Meridian’s molecular and immunoassay reagents can strengthen your STI assay performance from sample to result.
32 | GENengnews.com
Powered by FlippingBook